Previous close | 51.71 |
Open | 52.10 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 52.10 - 53.88 |
52-week range | 50.81 - 75.42 |
Volume | |
Avg. volume | 2,831 |
Market cap | 113.961M |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | 0.12 |
EPS (TTM) | 4.20 |
Earnings date | 30 July 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript April 30, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $0.746 EPS, expectations were $0.88. INCY isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello and welcome to Incyte First […]
Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
Incyte Corp on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%. The company is working on strengthening its pipeline to counter competition from newly approved drugs, which could impact sales of Jakafi, the company's biggest-selling drug, as it nears the loss of exclusivity later this decade. During the first quarter, the Delaware-based company gained worldwide exclusive global rights for Monjuvi, approved by the FDA for the treatment of certain kinds of blood cancer, from MorphoSys AG.